Article Text
Statistics from Altmetric.com
Key learning points
Finasteride is licensed for the treatment of benign prostatic hyperplasia and male pattern hair loss.
A previous safety alert has highlighted the risk of depression and suicidal thoughts associated with finasteride.
There is a need to raise awareness among healthcare professionals and patients of the risk of psychiatric and sexual adverse effects.
The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals to warn patients that finasteride is associated with psychiatric and sexual adverse effects that may persist after treatment has stopped.1
Overview
The MHRA has conducted a review into the safety of finasteride following concerns raised by patients about the apparent lack of awareness among healthcare professionals and patients of the risk of depression and suicidal thoughts associated with …
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.